U.S. health regulators will require generic versions of the best-selling painkiller OxyContin to include recent formulation changes designed to make the pill harder to abuse.
Apr 16, 2013
1
0
The shape of a man's face can help predict his sporting acumen, according to a study on Wednesday that found Japanese baseball players whose faces were relatively broad rather than long were most likely to hit a home run.
Apr 9, 2013
1
0
Researchers of the Psychiatry and Mental Health research group at the Bellvitge Biomedical Research Institute (IDIBELL), in the Bellvitge University Hospital, have shown that patient age influences the onset of pathological ...
Apr 8, 2013
0
0
(AP)—Struggling Anglo-Swedish drugmaker AstraZeneca PLC said Monday that it will eliminate 1,600 jobs, mostly in the U.S. and United Kingdom, as its new CEO starts a major research and development reorganization.
Mar 18, 2013
0
0
(HealthDay)—The final rule of the Department of Health and Human Services (HHS) Notice of Benefit and Payment Parameters for 2014, which expands on existing standards, has been released.
Mar 16, 2013
0
0
The U.S. Justice Department is investigating drug maker Sanofi's disclosures to the Food and Drug Administration about different responses to its blockbuster blood thinner Plavix.
Mar 11, 2013
0
0
(AP)—Anglo-Swedish pharmaceutical company AstraZeneca PLC warned over expiring patents on its medicines as the company announced a 37 percent fall in full-year net profit on Thursday.
Jan 31, 2013
0
0
Peers exert a greater influence on teenage girls' dissatisfaction with their bodies than do thin ideals in television or social media use, according to new research by Dr. Christopher J. Ferguson and colleagues from Texas ...
Jan 30, 2013
0
0
Pfizer Inc.'s fourth-quarter profit more than quadrupled, despite competition from generic drugs hurting sales of Lipitor and other medicines, because of a $4.8 billion gain from selling its nutrition business. The drugmaker's ...
Jan 29, 2013
0
0
(AP)—Eli Lilly and Co. said Friday its 2013 earnings will grow more than Wall Street expects, even though the drugmaker will lose U.S. patent protection for two more key products this year.
Jan 4, 2013
0
0
